Aldeyra TherapeuticsALDX
ALDX
About: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Employees: 9
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
58% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 24
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
40% more call options, than puts
Call options by funds: $5.07M | Put options by funds: $3.63M
4% more funds holding
Funds holding: 112 [Q3] → 117 (+5) [Q4]
0.57% more ownership
Funds ownership: 61.8% [Q3] → 62.37% (+0.57%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
6% less capital invested
Capital invested by funds: $197M [Q3] → $185M (-$11.2M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
599%
upside
Avg. target
$10
599%
upside
High target
$10
599%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Matthew Caufield 31% 1-year accuracy 20 / 64 met price target | 599%upside $10 | Buy Reiterated | 3 Mar 2025 |
Financial journalist opinion
Based on 8 articles about ALDX published over the past 30 days
Neutral
GlobeNewsWire
3 hours ago
ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock Drop Triggers Securities Investigation; Contact BFA Law if You Lost Money (NASDAQ:ALDX)
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
Neutral
GlobeNewsWire
3 hours ago
BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud After Shares Fall Nearly 75%; Investors Encouraged to Contact the Firm
Shares of Aldeyra Therapeutics are down nearly 75% today. Block & Leviton is investigating ALDX for potential securities fraud. Investors should reach out.
Negative
Proactive Investors
3 hours ago
Aldeyra Therapeutics tanks as FDA rejects investigational dry eye disease therapy
Aldeyra Therapeutics (NASDAQ:ALDX) shares plummeted more than 70% after the biotechnology company received a letter of refusal from the Food and Drug Administration (FDA) for its investigational dry eye disease therapy reproxalap. The company said the rejection was based on insufficient evidence of efficacy in treating ocular symptoms associated with dry eye disease.
Negative
Benzinga
5 hours ago
FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns
The U.S. Food and Drug Administration (FDA) on Thursday issued a Complete Response Letter for Aldeyra Therapeutics, Inc.'s ALDX resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for dry eye disease.
Negative
Reuters
6 hours ago
US FDA declines to approve Aldeyra's eye disease drug
The U.S. Food and Drug Administration has declined to approve Aldeyra Therapeutics' treatment for dry eye disease, the company said on Thursday.
Neutral
Business Wire
7 hours ago
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturin.
Neutral
Business Wire
3 weeks ago
Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida. Dr. Brady's conversation with Marc Goodman, Senior Managing Director,.
Positive
Seeking Alpha
4 weeks ago
Aldeyra Therapeutics Is Severely Undervalued Before PDUFA
Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA with a PDUFA date of April 2025. Despite a controversial deal with AbbVie, Aldeyra remains financially solid, with $100M in cash and potential milestone payments. The DED market is strong, and reproxalap's data surpasses competitors, indicating significant undervaluation of Aldeyra's stock.
Neutral
Business Wire
1 month ago
Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The conference is being conducted virtually on February 11, 2025. Dr. Brady's co.
Positive
Seeking Alpha
3 months ago
Aldeyra Therapeutics: Key Inflection Point Ahead
Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Drug giant AbbVie has a significant option agreement on Aldeyra's primary pipeline asset that will likely be triggered upon FDA approval in April. An updated analysis around Aldeyra Therapeutics follows in the paragraphs below.
Charts implemented using Lightweight Charts™